Barrett Katz
CIK 1841628 · View on SEC EDGAR ↗
First SEC filing: Jan. 21, 2021 · Latest: Jan. 21, 2021
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 17, 2023 | VRDN | S 10b5-1 | 24,853 | $37.21 | $924,780 | 0 Direct | -100.00% | Disposed | -35.1% (price as of 2026-08-20) |
| Jan. 13, 2023 | VRDN | S 10b5-1 | 4,147 | $37.01 | $153,480 | 0 Direct | -100.00% | Disposed | -34.7% (price as of 2026-08-20) |
| Jan. 10, 2023 | VRDN | S 10b5-1 | 47,377 | $35.30 | $1,672,408 | 0 Direct | -100.00% | Disposed | -31.6% (price as of 2026-08-20) |
| Jan. 9, 2023 | VRDN | S 10b5-1 | 12,623 | $33.04 | $417,064 | 0 Direct | -100.00% | Disposed | -26.9% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 8, 2023 | VRDN | Stock Option (Right to Buy) | Common Stock (108,000) | $34.20 | Feb. 8, 2033 | 108,000 | Acquired |
| Jan. 17, 2023 | VRDN | Stock Option (Right to Buy) | Common Stock (24,853) | $23.03 | Jan. 17, 2031 | 24,853 | Disposed |
| Jan. 13, 2023 | VRDN | Stock Option (Right to Buy) | Common Stock (4,147) | $23.03 | Jan. 17, 2031 | 4,147 | Disposed |
| Jan. 10, 2023 | VRDN | Stock Option (Right to Buy) | Common Stock (47,377) | $23.03 | Jan. 17, 2031 | 47,377 | Disposed |
| Jan. 9, 2023 | VRDN | Stock Option (Right to Buy) | Common Stock (12,623) | $23.03 | Jan. 17, 2031 | 12,623 | Disposed |
| Feb. 2, 2022 | VRDN | Stock Option (Right to Buy) | Common Stock (110,000) | $18.51 | Feb. 2, 2032 | 110,000 | Acquired |
| Jan. 18, 2021 | VRDN | Employee Stock Option (right to buy) | Common Stock (356,000) | $23.03 | Jan. 17, 2031 | 356,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
VRDN
Former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $5,707 | — | — | — | — | — | $1,090,915 | $2,160,823 |
| 2023 | $502,228 | — | — | — | — | — | $9,888 | $3,275,999 |
| 2022 | $487,600 | $136,528 | — | — | — | — | $11,488 | $2,110,655 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.